MX2021008525A - Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. - Google Patents
Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.Info
- Publication number
- MX2021008525A MX2021008525A MX2021008525A MX2021008525A MX2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A MX 2021008525 A MX2021008525 A MX 2021008525A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- interleukin
- therapy
- mutated
- cytokine
- Prior art date
Links
- 102100033499 Interleukin-34 Human genes 0.000 title abstract 5
- 101710181549 Interleukin-34 Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 230000007512 neuronal protection Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2334—Interleukin-34 (IL-34)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305046 | 2019-01-15 | ||
PCT/EP2020/050920 WO2020148338A1 (en) | 2019-01-15 | 2020-01-15 | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008525A true MX2021008525A (es) | 2021-11-12 |
Family
ID=65228484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008525A MX2021008525A (es) | 2019-01-15 | 2020-01-15 | Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. |
Country Status (12)
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819614B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 |
WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR520E (fr) | 1901-11-13 | 1903-01-26 | Bermont Victor Etienne | Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5) |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
DE69032284T2 (de) | 1989-03-21 | 1998-10-08 | Vical, Inc., San Diego, Calif. | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
EP0689601B1 (en) | 1993-02-22 | 2006-10-04 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EA006972B1 (ru) | 1998-12-23 | 2006-06-30 | Пфайзер Инк. | Моноклональное антитело человека к ctla-4 и способы его применения |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
KR100864120B1 (ko) | 2000-07-03 | 2008-10-16 | 브리스톨-마이어스스퀴브컴파니 | 가용성 ctla4 분자를 사용한 류마티스성 질환의 치료법 |
PL206018B1 (pl) | 2001-10-19 | 2010-06-30 | Isotechnika Inc | Preparat farmaceutyczny, sposób jego wytwarzania, mikroemulsja i zastosowanie tego preparatu farmaceutycznego |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
US20070264277A1 (en) * | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
DK1962886T4 (da) | 2005-12-20 | 2022-05-02 | Bristol Myers Squibb Co | Stabile proteinformuleringer |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
ES2571235T3 (es) | 2009-04-10 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 |
US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
TWI629483B (zh) | 2010-06-11 | 2018-07-11 | 協和醱酵麒麟有限公司 | anti-TIM-3 antibody |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
BR112015021999A8 (pt) | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
CA2922655A1 (en) | 2013-09-06 | 2015-03-12 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
JP6521977B2 (ja) | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 免疫調節剤としての1,2,4−オキサジアゾール誘導体 |
EP3169350B1 (en) * | 2014-07-17 | 2019-01-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases |
CN106084030B (zh) * | 2016-04-25 | 2019-11-08 | 北京大学 | 一种提高白细胞介素il-34热稳定性的方法 |
-
2020
- 2020-01-15 KR KR1020217024902A patent/KR20210121077A/ko unknown
- 2020-01-15 BR BR112021013944A patent/BR112021013944A8/pt unknown
- 2020-01-15 SG SG11202107606VA patent/SG11202107606VA/en unknown
- 2020-01-15 CN CN202080017907.2A patent/CN113508129A/zh active Pending
- 2020-01-15 MX MX2021008525A patent/MX2021008525A/es unknown
- 2020-01-15 CA CA3126741A patent/CA3126741A1/en active Pending
- 2020-01-15 US US17/422,556 patent/US20220098264A1/en active Pending
- 2020-01-15 JP JP2021540589A patent/JP2022517029A/ja active Pending
- 2020-01-15 EP EP20700307.0A patent/EP3911670A1/en active Pending
- 2020-01-15 AU AU2020208909A patent/AU2020208909A1/en active Pending
- 2020-01-15 WO PCT/EP2020/050920 patent/WO2020148338A1/en unknown
-
2021
- 2021-07-14 IL IL284868A patent/IL284868A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3911670A1 (en) | 2021-11-24 |
WO2020148338A1 (en) | 2020-07-23 |
SG11202107606VA (en) | 2021-08-30 |
CN113508129A (zh) | 2021-10-15 |
KR20210121077A (ko) | 2021-10-07 |
JP2022517029A (ja) | 2022-03-03 |
AU2020208909A1 (en) | 2021-07-29 |
BR112021013944A2 (US06244707-20010612-C00011.png) | 2021-11-21 |
BR112021013944A8 (pt) | 2023-02-07 |
IL284868A (en) | 2021-08-31 |
US20220098264A1 (en) | 2022-03-31 |
CA3126741A1 (en) | 2020-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008525A (es) | Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia. | |
TWD217252S (zh) | 充電器 | |
MX2022001018A (es) | Electrodos metalicos de bajo costo. | |
MX2020001332A (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas. | |
MX2023002982A (es) | Inhibidores de la interaccion de menina-leucemia de linaje mixto. | |
AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
EP2839927A3 (en) | A surface processing system for a work piece | |
HK1138011A1 (en) | Template-fixed peptidomimetics | |
MX2022005411A (es) | COMPUESTOS DE UNIÓN A IL-2RßYC. | |
MX2023001226A (es) | Anticuerpos anti-lag-3. | |
TN2019000122A1 (en) | Method for increasing the secretion levels of interleukin 2 and proteins derived from it | |
EP4292664A3 (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
JOP20220083A1 (ar) | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr | |
PH12018500492A1 (en) | Charge/discharge control device, charge/discharge control system, and charge/discharge control method | |
MX2017006408A (es) | Linfocitos t gamma delta modificados geneticamente. | |
MA38477B1 (fr) | Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs | |
MX2021003797A (es) | Terapias inmunoablativas. | |
TWD210683S (zh) | 電池 | |
MX2018004723A (es) | Aparato de trabajo de placa de vidrio. | |
WO2018222379A3 (en) | SOLID STATE LITHIUM-METAL BATTERY BASED ON THREE-DIMENSIONAL ELECTRODE DESIGN | |
UY27662A1 (es) | Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny. | |
WO2019045805A3 (en) | PROCESS FOR METALLIZING ELECTROCHEMICALLY ACTIVE POWDERS | |
CN206211399U (zh) | 一种闭式卡具 | |
WO2023076912A3 (en) | Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies | |
WO2022261455A3 (en) | Genetically-modified saccharomyces yeast strains as preventative and therapeutic agents |